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plan in US covering 4 million lives. Outcomes measure was any occurrence of CV
including ischemic heart disease, cerebrovascular disease, and peripheral vascular 
disease. A multivariate logistic model was developed to evaluate adjusted CV-risk. 
Multicollinearity test and Hosemer-Lemeshow test were performed. RESULTS:
Mean(/SD) age was 57(/8) years in combo-group(N  53) and 57(/11) years
in mono-group(N  5670). In combo-group, mean(/SD) treatment-duration
was 779(/424) days for statinﬁ brate combination-therapy. In mono-group, 
mean(/SD) treatment-duration was 987(/588) days for statin-monotherapy. 
Unadjusted CV-rates of combo-group versus mono-group were not signiﬁ cantly dif-
ferent (odds ratio [OR]  1.39, P  0.2313). Although adjusting for age, gender, prior 
CV, CV related pharmacy-costs, total medical-costs, diabetes with complication, and 
Elixhauser-comorbidity, CV-rates of combo-group versus mono-group were not sig-
niﬁ cantly different (OR  1.186, P  0.5929). All covariates were signiﬁ cantly associ-
ated with CV-rates. The model did not suffer from multicollinearity and the model
goodness-of-ﬁ t was satisfactory (P  0.5575). CONCLUSIONS: In a managed care 
population with type-II diabetes after adjusting for known baseline differences, CV-
risks among subjects who used statinﬁ brate combination-therapy compared to those 
who used statin-monotherapy did not signiﬁ cantly differ. This is different from what 
people expected for the combination-therapy, due to low power resulting from small 
sample size for combo-group. We hope this result will be useful in health policy to
ﬁ nd treatment strategies to reduce CV-risk in diabetics. Future research is in progress
to address the causality behind this association.
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OBJECTIVES: There is limited evidence of comparative effectiveness of individual
Angiotensin Converting Enzyme (ACE) inhibitors for treatment of heart failure. We 
compared the clinical effectiveness in patients with Chronic Heart Failure (CHF). 
METHODS: The study was a retrospective analysis of a national cohort of patients
diagnosed with CHF from October 1, 1996 through September 30, 2003 identiﬁ ed 
from the Department of Veterans Affairs electronic medical records system. The
independent variables of interest were individual ACE inhibitors treatment groups:
Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Quinapril, and Ramipril. 
Outcome assessed was death within one year. Cox-proportional hazards analysis was
employed to assess the adjusted association between these treatments and mortality
within one year after controlling for demographic factors, duration of CHF, comor-
bidities and comedications. RESULTS: A total of 188,445 patients with CHF were
identiﬁ ed. Majority of the patients were males (94.74%) and whites (53.68%). Lisino-
pril (71.93%) was the most commonly prescribed ACE Inhibitor followed by Fosino-
pril (20.90%) and Captopril (6.39%). In the multivariable model, Enalapril, adjusted
hazard ratio 0.715 (95% CI: 0.584 – 0.876), Fosinopril, adjusted hazard ratio 0.778 
(95% CI: 0.729–0.830), and Lisinopril 0.784 (95% 0.740–0.831) were found to have 
a statistically signiﬁ cant protective effect as compared to Captopril (referent group). 
Benazepril, Ramipril, and Quinapril were not statistically signiﬁ cantly different from 
Captopril effect. CONCLUSIONS: Enalapril, Fosinopril and Lisinopril were associ-
ated with signiﬁ cantly reduced risk of death within one year. Further research is needed 
to examine other outcomes including cost-effectiveness of ACE inhibitor use in the 
treatment of heart failure.
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OBJECTIVES: There is limited evidence of comparative effectiveness of Angiotensin 
Receptor Blockers (ARBs) for the treatment of Chronic Heart Failure (CHF). We 
compared the clinical effectiveness of Losartan, Valsartan,Candesartan, Telmisartan
and Irbesartan in patients with CHF. METHODS: The study was a retrospective 
cohort study utilizing national Veterans Affairs electronic medical records. The cohort 
consisted of all heart failure patients diagnosed between October 1, 1997 to September
30, 2002. After excluding patients with any exposure to ARBs within the previous 6
months, new exposure to ARBs was determined between the index date (October 1, 
2000) and the study end date (September 30, 2002) and subsequent time to death was
measured concurrently during that period. Five treatment groups were deﬁ ned based
on initial use of: Candesartan, Valsartan, Losartan, Irbesartan, and Telmisartan.
Multiple Cox proportional hazards regression analysis was employed to assess the
adjusted association between these treatments and time to death after controlling for 
demographics, hospitalization, years with CHF, 30 comorbidities and comedications.
Losartan was chosen as the reference drug because it was the ﬁ rst ARB introduced 
into the market. RESULTS: Total 19,186 patients were identiﬁ ed. Majority of the 
patients were male (98.06%).The most common comorbid condition in the cohort 
was hypertension(81.17%) followed by Ischemic Heart Disease(68.65%) and diabe-
tes(48.46%). Irbesartan (55.50%) was the most commonly prescribed ARB followed 
by Losartan (19.44%). In the multivariable model losartan was found to have a sta-
tistically signiﬁ cant decreased risk as compared to telmisartan, adjusted hazard ratio 
for telmisartan was 1.66 (95% CI: 1.12 – 2.46).Irbesartan, Valsartan, and Candesar-
tan were not statistically signiﬁ cantly different from Losartan. CONCLUSIONS: All
of the ARBs had similar associations with time to death, except telmisartan, which
had a statistically increased risk of mortality within two years. Further research is 
needed to examine other outcomes including cost-effectiveness in the treatment of 
heart failure.
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OBJECTIVES: To assess the clinical effectiveness of point-of-care (POC) INR monitor-
ing devices for patient on long-term oral anticoagulation therapy (OAT). METHODS:
A systematic review of the clinical literature was performed. Seventeen RCT studies 
published between January 1996 and November 2008 comparing POC devices to
routine anticoagulation control were included in the analysis. RESULTS: Of the 17
studies included in the analysis, 15 studies compared patient self-management or self-
testing to routine anticoagulation control and 2 studies examined the use of POC 
devices by primary health care practitioners. There was variation among the studies
regarding observation periods, indication for OAT and overall study quality. Based
on pooled analyses, there was no signiﬁ cant difference in major hemorrhagic events 
between patients in POC monitoring groups and usual care controls (OR 0.77, 95% 
CI 0.54, 1.10). POC monitoring resulted in signiﬁ cantly fewer thromboembolic events
(OR 0.56, 95% CI 0.39, 0.80) and deaths (OR 0.63, 95% CI 0.41, 0.97) compared
with usual care. Subgroup analyses included POC strategy, control strategy, indication 
for OAT, study quality, length of follow-up and industry sponsored. Mean time in the
therapeutic range was pooled across studies and weighted by the number of patient-
years of observation to assess INR control. The POC monitoring patients were in
range 68.6% of the time compared with 64.3% of time in usual care controls. Data 
were deemed unreliable to estimate 95% CI for pooled estimates. Higher testing fre-
quency and more intensive patient education in the POC monitoring groups may also 
partially explain observed differences in clinical outcomes. CONCLUSIONS: The 
review of clinical evidence suggest that using POC monitoring devices for patients on 
long-term OAT results in signiﬁ cantly fewer deaths and thromboembolic events and 
may result in better INR control than conventional laboratory testing. Nevertheless,
the use of POC devices should factor patient suitability, health system constraints and 
affordability.
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OBJECTIVES: Fondaparinux was shown to be non-inferior to enoxaparin in treat-
ment of deep vein thrombosis (DVT) in a clinical trial setting. Comparisons of out-
comes between these agents for treatment of DVT or pulmonary embolism (PE) in a 
naturalistic setting are not known. Objective of this study was to evaluate real-world 
economic outcomes of fondaparinux vs. enoxaparin for inpatient treatment of venous 
thromboemolism (VTE). METHODS: Retrospective analysis of discharge data from 
over 550 US acute care hospitals was conducted to evaluate and compare economic 
outcomes of patients receiving fondaparinux or enoxaparin for VTE treatment. Dis-
charges containing ICD-9 diagnosis codes for VTE (DVT, PE or both) were included.
Total hospital charges and index anticoagulant charges were captured for initial admis-
sion and any readmissions for VTE within 30-day follow-up. Demographic, clinical, 
and hospital descriptive measures were used to compare two treatment cohorts 
and to inform multivariate models. Expenditures in fondaparinux and enoxaparin 
cohorts were compared using a generalized linear methods (GLM) approach. 
RESULTS: Fondaparinux patients (n  366) were younger (61 vs. 64, p  0.001) 
than enoxaparin patients (n  14,674) and had more severe illness proﬁ les (APR DRG 
3.18 vs. 3.07, p  0.024). Average unadjusted charges for initial admission across 
the two groups were $76,352. Adjusted difference in charges for initial admission 
between fondaparinux and enoxaparin was not statistically signiﬁ cant (difference 
$574; p  0.906). Average unadjusted charges for overall study period including 30-
day follow-up were $80,764. Adjusted difference in charges between two groups was 
not statistically signiﬁ cant (difference  $3,633; p  0.536). Charges for index antico-
agulant during initial admission were $2233 for fondaparinux and $2497 for enoxa-
parin (p  0.108). After multivariate adjustment, this difference was signiﬁ cantly lower
in favor of fondaparinux (difference  $409, p  0.001). CONCLUSIONS: These 
real-world economic outcomes corroborate clinical trial ﬁ ndings supporting non-
inferiority of fondaparinux compared to enoxaparin for VTE treatment, as measured
by hospital charges. Further analyses of clinical outcomes in a naturalistic setting are 
warranted.
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OBJECTIVES: Untreated cholesterol increases with age. Furthermore, there are 
medical conditions requiring more aggressive lipid lowering, which become more 
prevalent with age; hence impacting the relationship between cholesterol and age. The
